Hepatitis B Foundation Welcomes International Leaders to Its Scientific and Medical Advisory Board
Doylestown, PA (February 2017) -- The Hepatitis B Foundation is pleased to announce that two internationally renowned experts in the area of viral hepatitis have joined its Scientific and Medical Advisory Board. Francis Chisari, MD, recently retired from Scripps Research Institute, and Robert P. Perrillo, MD, FAASLD, of Baylor University Medical Center, were both appointed to the foundation’s distinguished advisory board.
“The Hepatitis B Foundation is proud to have Drs. Chisari and Perrillo join our Scientific and Medical Advisory Board,” said Timothy M. Block, PhD, president and co-founder of the Hepatitis B Foundation. “Both are highly accomplished scientists who have made significant contributions to advancing the science and medicine of hepatitis B. Their involvement will strengthen our organization and improve how we serve those with hepatitis B worldwide.”
Dr. Chisari recently retired from the Scripps Research Institute where he served as professor and head of the Division of Experimental Pathology in the Department of Molecular and Experimental Medicine. His research is internationally recognized and focused on host-virus interactions that determine the outcome of viral infections, using the hepatitis B virus (HBV) and the hepatitis C virus (HCV) as models. Dr. Chisari has received numerous honors and awards for his scientific achievements, including the Ernst Jung Prize in Medicine, the Rous Whipple Award of the American Society of Investigative Pathology, and the Distinguished Scientific Achievement Award of the American Association for the Study of Liver Diseases. He holds numerous patents, serves on many scientific advisory boards, and is a frequent keynote lecturer. Dr. Chisari received his Medical Degree from Cornell University Medical College and is Board Certified in Internal Medicine and Anatomic Pathology.
Dr. Perrillo, senior research hepatologist, Hepatology Division of Baylor University Medical Center in Dallas, and adjunct professor of Medicine, University of Texas Southwestern,is an international opinion leader and educator with more than 200 published papers and a nearly 40 year career of clinical research in hepatitis B. He was the lead investigator of the U.S. multicenter study that described the safety and efficacy of alpha interferon in chronic hepatitis B, which became the first approved drug for hepatitis B in 1992. He was one of first investigators to explore oral nucleoside analogue therapy (adenine arabinoside) to treat hepatitis B in the early 1980’s and the first to publish on adefovir’s efficacy for lamivudine resistant hepatitis B, both in the transplant and non-transplant settings. Dr. Perrillo received his Medical Degree from Georgetown University and completed his Gastroenterology fellowship training at Washington University.
About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900.
# # #